Positive Phase III data for etranacogene dezaparvove for patients with moderate to moderately severe haemophilia B

In the study of 54 adult males, a 30-minute IV infusion of etranacogene dezaparvove increased blood clotting factor IX activity from ≤2% at baseline to a mean of 37.2% at 26 weeks, meeting the primary endpoint. In addition, 72% of patients reported no bleeding episodes.

Source:

Biospace Inc.